Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 921-577-3 | CAS number: 1174918-60-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 1996-07-25 to 1997-04-11
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable without restriction because it is was performed according to GLPs and in compliance with OECD principles 414.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.31 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Pentane
- EC Number:
- 203-692-4
- EC Name:
- Pentane
- Cas Number:
- 109-66-0
- Molecular formula:
- C5H12
- IUPAC Name:
- pentane
- Details on test material:
- - Name of test material (as cited in study report): n-pentane
- Substance type: C5 aliphatic
- Physical state: liquid
- Analytical purity: 97.4% (considered pure for purpose of dosing)
- Lot/batch No.: 2036924
- Expiration date of the lot/batch: June 2001
- Stability under test conditions: 7 days at 2% and 20% w/v
- Storage condition of test material: refrigerated
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD BR VAF/Plus
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Portage, Michigan
- Age at study initiation: 14 to 16 weeks (females)
- Weight at study initiation: 243 to 316 grams (females)
- Fasting period before study: no
- Housing: individually-housed except during mating in suspended stainless-steel, wire mesh cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 20 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 24
- Humidity (%): 40 to 70
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark
- IN-LIFE DATES: From: 1996-10-07 To: 1996-11-08
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Test material formulations were prepared weekly by mixing appropriate amounts of test material with vehicle; test-material formulations were divided into individual samples for each day and stored in a refrigerator until needed.
VEHICLE
- Justification for use and choice of vehicle (if other than water): test material was soluble in carrier
- Concentration in vehicle: not reported
- Amount of vehicle (if gavage): not reported
- Lot/batch no. (if required): not reported
- Purity: not reported - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test material formulations were evaluated for stability, homogeneity, and achieved concentration. Stability and homogeneity were evaluated prior to the start of the study as part of the dose-range finding study (Study no. 157533; achieved concentration was evaluated on the first and third dosing mixture preparations. Results from the dose-range finding study indicate that the test material formulations were stable for at least 7 days at 2% and 20% w/v and homogenous (with the relative standard deviation being 1% for both sample sets). Test material formulations were found to be within 16% of the nominal concentration.
- Details on mating procedure:
- - Impregnation procedure: [artificial insemination / purchased timed pregnant / cohoused]: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: not reported
- Females were placed in cage with male. After confirmation of mating, each female was returned to its own cage. New females were then placed in the males' cages until the required number of mated females was obtained by continuous cohabitation in consideration of lab scheduling.
- Further matings after two unsuccessful attempts: not reported
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: vaginal plug and/or sperm in vaginal rinse referred to as day 0 of pregnancy - Duration of treatment / exposure:
- gestation day (gd) 6 though 15
- Frequency of treatment:
- daily
- Duration of test:
- IN-LIFE DATES: From: 1996-10-07 To: 1996-11-08
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 100, 500, or 1000 mg/kg/day
Basis:
nominal conc.
Dosing volumes were 5 mL/kg and based on the most recent individual body weights
- No. of animals per sex per dose:
- 25 dams per group
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: A dose-range finding study (Study no. 157533), in which rats were dosed with n-pentane via gavage at levels of 0, 250, 500, 750, and 1000 mg/kg. Maternal signs of toxicity were observed at 1000 mg/kg and included decreased body weight gain and food consumption over the treatment period and overall gestation interval; no other signs of toxicity were observed in dams or fetuses.
- Rationale for animal assignment (if not random): Mated females were assigned to dose groups in the order of mating.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least twice daily during treatment and at least once daily at other times during the study
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily during gestation
BODY WEIGHT: Yes
- Time schedule for examinations: gd 0, 6, 9, 12, 15, 18, and 21
FOOD CONSUMPTION: Yes
- Time schedule for examinations: gd 0, 6, 9, 12, 15, 18, and 21
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 21
- Organs examined: Ovaries
OTHER: Surviving dams and those that delivered prior to scheduled necropsy were scarified by carbon dioxide asphyxiation and exsanguination. Dams that delivered prior to scheduled necropsy were examined for gross lesions, and the number of implantation sites or concepti in each horn was counted. Surviving dams were necropsied, and uterine weight with ovaries attached was recorded. Uteri of all non-pregnant females were stained with ammonium sulfide to confirm pregnancy status. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: yes
Examinations included:
- Gravid uterus weight: yes
- Number of corpora lutea: yes
- Number of implantations: yes
- Number of early resorptions: yes
- Number of late resorptions: yes
- Other: location of implantations - Fetal examinations:
- - External examinations: yes: all per litter (number of live and dead fetuses was counted; fetuses were weighed, sexed, and examined for gross malformations)
- Soft tissue examinations: yes: half per litter
- Skeletal examinations: yes: half per litter
- Head examinations: yes: half per litter - Statistics:
- Statistical methods used are presented in the table below. Statistical evaluation of equality of means was conducted by a one-way analysis of variance and a test for ordered response in dose groups. Equal variances were evaluated by Bartlett's test. Equal variances were then tested using parametric methods, otherwise nonparametric techniques were used. Percentages, where appropriate, were calculated and transformed by Cochran's transformation, followed by the arc sine transformation. Both raw and transformed percentages were tested for statistical significance. The Bartlett's test was conducted at the 1% level of significance; all other tests were conducted at the 5% and 1% level of significance.
- Indices:
- preimplantation loss
postimplantation loss - Historical control data:
- not provided
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
There were no treatment-related changes in mean body weight, body weight gain, uterine weight, corrected body weight, food consumption, or uterine implantation data. There were no treatment-related mortalities or clinical signs of toxicity.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
There were no treatment-related changes in growth or increased fetal death. There were no changes in total malformations or variations.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
a Data obtained from pages 28 -29 in the study report.
Cesarean section observationsa |
||||
Observation |
Dose (mg/kg bw/day) |
|||
0 |
100 |
500 |
1000 |
|
No. Animals assigned (mated) |
25 |
25 |
25 |
25 |
No. Animals pregnant |
24 |
25 |
23 |
25 |
Pregnancy rate (%) |
96 |
100 |
92 |
100 |
No. Nonpregnant |
1 |
0 |
2 |
0 |
Maternal wastage |
|
|
|
|
No. died |
0 |
0 |
0 |
0 |
No. Died pregnant |
0 |
0 |
0 |
0 |
No. Died nonpregnant |
0 |
0 |
0 |
0 |
No. Aborted |
0 |
0 |
0 |
0 |
No. Premature delivery |
1 |
1 |
0 |
0 |
Corpora lutea/Dam |
15.26±1.63 |
15.88±1.68 |
15.43±1.78 |
15.68±2.21 |
Implantations/Dam |
14.52±1.70 |
14.88±2.33 |
14.83±1.83 |
15.16±2.32 |
Total No. litters |
23 |
24 |
23 |
25 |
Total number of live fetuses Live fetuses/Dam |
310 13.48±1.78 |
346 14.42±2.26 |
318 13.83±2.19 |
359 14.36±2.29 |
Total number of dead fetuses Dead fetuses/Dam |
0 0.0±0.0 |
0 0.0±0.0 |
0 0.0±0.0 |
0 0.0±0.0 |
Total No. resorptions |
24 |
11 |
23 |
19 |
Early |
22 |
11 |
23 |
18 |
Late |
2 |
0 |
0 |
1 |
Resorptions/Dam |
1.04±0.98 |
0.46±0.59 |
1.00±0.95 |
0.76±0.83 |
Early |
0.96±0.98 |
0.46±0.59 |
1.00±0.95 |
0.72±0.84 |
Late |
0.09±0.29 |
0.0±0.0 |
0.0±0.0 |
0.04±0.20 |
Litters with total resorptions |
0 |
0 |
0 |
0 |
Mean fetal weight (g) |
0 |
0 |
0 |
0 |
Males |
5.34±0.38 |
5.45±5.40 |
5.40±0.44 |
5.42±0.46 |
Females |
5.13±0.40 |
5.12±0.37 |
5.21±0.37 |
5.14±0.55 |
Sex ratio (% male) |
49 |
49 |
47 |
50 |
Preimplantation loss (%) |
4.6±7.8 |
6.3±12.5 |
4.0±5.3 |
3.5±4.7 |
Postimplantation loss (%) |
7.1±6.5 |
3.0±3.7 |
7.0±7.0 |
5.3±5.6 |
a Data obtained from pages 32 -34 and 73 -167 in the study report.
External examinationsa |
||||
Observationsb |
Dose (mg/kg bw/day) |
|||
0 |
100 |
500 |
1000 |
|
No. Fetuses (litters) examined |
309 (23) |
346 (24) |
318 (23) |
359 (25) |
No. Fetuses (litters) affected with variations |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
No. Fetuses (litters) affected with malformations |
0 (0) |
0 (0) |
1 (1) |
1 (1) |
a Data obtained from pages 35 in the study report.
b Some observations may be grouped together.
c Fetal (litter) incidence
Visceral examinationsa |
||||
Observationsb |
Dose (mg/kg bw/day) |
|||
0 |
100 |
500 |
1000 |
|
No. Fetuses (litters) examined |
156 (23) |
172 (24) |
161 (23) |
178 (25) |
No. Fetuses (litters) affected with variations |
0 (0) |
3 (2) |
2 (2) |
1 (1) |
No. Fetuses (litters) affected with malformations |
4 (3) |
7 (4) |
2 (2) |
9 (6) |
a Data obtained from page 35 in the study report.
b Some observations may be grouped together.
c Fetal (litter) incidence
Skeletal examinationsa |
||||
Observationsb |
Dose (mg/kg bw/day) |
|||
0 |
100 |
500 |
1000 |
|
No. Fetuses (litters) examined |
154 (23) |
174 (24) |
157 (23) |
181 (25) |
No. Fetuses (litters) affected with variations |
27 (14) |
31 (13) |
25 (13) |
44 (17) |
No. Fetuses (litters) affected with malformations |
0 (0) |
0 (0) |
1 (1) |
0 (0) |
aData obtained from page 35 in the study report.
bSome observations may be grouped together.
cFetal (litter) incidence
Applicant's summary and conclusion
- Conclusions:
- There were no signs of maternal toxicity at any dose level. There were no treatment-related changes in mean body weight, body weight gain, uterine weight, corrected body weight, food consumption, or uterine implantation data. There were no treatment-related mortalities or clinical signs of toxicity. The maternal NOAEL is 1000 mg/kg/day.
There were no signs of developmental toxicity at any dose level. There were no treatment-related changes in growth or increased fetal death. There were no changes in total malformations or variations. The developmental NOAEL is 1000 mg/kg/day. - Executive summary:
In a developmental toxicity study, n-pentane was orally administered via gavage to 25 Crl:CD BR VAF rats per dose at dose levels of 0, 100, 500, or 1000 mg/kg bw/day from days 6 through 15 of gestation. There were no signs of maternal toxicity at any dose level. There were no treatment-related changes in mean body weight, body weight gain, uterine weight, corrected body weight, food consumption, or uterine implantation data. There were no treatment-related mortalities or clinical signs of toxicity. A maternotoxic dose was not used. However, the highest dose tested was 1000 mg/kg/day, and no adverse effects were observed. In general, the highest dose tested does not need to exceed 1000 mg/kg/day unless potential human exposure data indicate the need for higher doses. Therefore, the study reported a maternal NOAEL of 1000 mg/kg/day.
There were no signs of developmental toxicity at any dose level. There were no treatment-related changes in growth or increased fetal death. There were no changes in total malformations or variations. The developmental NOAEL is 1000 mg/kg/day.
This study received a Klimisch score of 1 and is classified as reliable without restriction because it was performed according to GLPs and in compliance with OECD principles 414.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.